Personalized cancer therapy for ovarian cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on evaluating the benefits of personalized treatment recommendations for patients with homologous recombination proficient (HRP) or HRD negative ovarian cancer. By utilizing multi-modal tumor profiling, the study aims to create a molecular summary report that informs a specialized molecular tumor board in recommending tailored therapies. The goal is to improve treatment outcomes for newly diagnosed patients who are treatment naïve and have limited options beyond standard chemotherapy. The usability of these personalized recommendations in clinical practice will also be assessed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
* No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
* Envisaged surgical candidate for interval debulking after 2 cycles of treatment
* Patients have adequate hematology, liver and kidney functions
* Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures
* ECOG 0-2
* Written informed consent according to national legal and regulatory requirements prior to any project specific procedures

Exclusion Criteria:

* ECOG ≥3
* Pregnant or lactating women
* Any other malignancy within the last 5 years which has an impact on the prognosis of the patient
* Concurrent participation in another clinical trial on the same indication
* Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance

Where it's running

• Kantonsspital Baden AG
  Baden, Canton of Aargau, Switzerland Recruiting
• Universitätsspital Basel
  Basel, Canton of Basel-City, Switzerland Recruiting
• HOCH Health Ostschweiz Kantonsspital St.Gallen
  Sankt Gallen, Canton of St. Gallen, Switzerland Recruiting
• Thurgau AG Frauenfeld / Münsterlingen
  Frauenfeld, Thurgau, Switzerland Recruiting
• Inselspital Bern (University Hospital for Medical Oncology)
  Bern, Switzerland Recruiting
• HFR-Fribourg- Hopital Cantonal
  Fribourg, Switzerland Recruiting

Study contacts

• Principal investigator: Viola Heinzelmann-Schwarz, Prof. — University Hospital Basel, Head Women's Hospital
• Study coordinator: Maren S Vogel, PhD
• Email: maren.vogel@usb.ch
• Phone: +41 61 3284203

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using letrozole as maintenance therapy for ovarian cancer

  This study is testing if adding letrozole to standard treatment helps women with estrogen-receptor positive ovarian cancer live longer without their cancer getting worse after surgery and chemotherapy.

  Recruiting at 51 sites Phase 3 Swiss GO Trial Group · Graz and 52 other locations · NCT04111978

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• Study of how tranexamic acid works in ovarian cancer patients

  This study is testing how well tranexamic acid works in reducing blood loss during surgery for women with advanced ovarian cancer by comparing two different ways of giving the medication.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06728670

• Comparing open and robotic surgery for women with complex pelvic masses

  This study is testing whether open surgery or robotic surgery is better for women with suspicious pelvic masses that are 8 cm or smaller.

  Recruiting Royal Surrey County Hospital NHS Foundation Trust · Guildford · NCT06638593

• Evaluating a new treatment for advanced malignant tumors

  This study is testing a new drug called BMS-986463 to see if it is safe and effective for people with advanced cancers like ovarian and lung cancer.

  Recruiting at 7 sites Phase 1 Bristol-Myers Squibb · Los Angeles, California and 16 other locations · NCT06476808

• Using a uterine wash and a blood protein test to find ovarian cancer early

  This project will try to find tumor DNA in a uterine wash plus protein markers in blood to detect ovarian or fallopian tube cancer in women having surgery for a suspected ovarian growth or BRCA1/2 carriers having risk-reducing surgery.

  Recruiting at 5 sites Massachusetts General Hospital · Little Rock, Arkansas and 5 other locations · NCT04794322

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.